|
Myeloid Neoplasia
Citations 21-30 of 176 total displayed.
|
Past content
(since Jan 2009):
|
Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice
- Briony A. Cutts, Anna-Karin M. Sjogren, Karin M. E. Andersson, Annika M. Wahlstrom, Christin Karlsson, Birgitta Swolin, and Martin O. Bergo
Blood 2009; 114: 3629-3632.
[Abstract]
[Full text]
[PDF]
How I monitor residual disease in chronic myeloid leukemia
- Jerald P. Radich
Blood 2009; 114: 3376-3381.
[Abstract]
[Full text]
[PDF]
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- Francesco Parlati, Susan J. Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, James B. Lorens, David R. Micklem, Paulina Ruurs, Catherine Sylvain, Yan Lu, Kevin D. Shenk, and Mark K. Bennett
Blood 2009; 114: 3439-3447.
[Abstract]
[Full text]
[PDF]
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- Maria E. Figueroa, Lucy Skrabanek, Yushan Li, Anchalee Jiemjit, Tamer E. Fandy, Elisabeth Paietta, Hugo Fernandez, Martin S. Tallman, John M. Greally, Hetty Carraway, Jonathan D. Licht, Steven D. Gore, and Ari Melnick
Blood 2009; 114: 3448-3458.
[Abstract]
[Full text]
[PDF]
Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
- Jennifer L. Snead, Thomas O'Hare, Lauren T. Adrian, Christopher A. Eide, Thoralf Lange, Brian J. Druker, and Michael W. Deininger
Blood 2009; 114: 3459-3463.
[Abstract]
[Full text]
[PDF]
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
- Olivier Kosmider, Véronique Gelsi-Boyer, Meyling Cheok, Sophie Grabar, Véronique Della-Valle, Françoise Picard, Franck Viguié, Bruno Quesnel, Odile Beyne-Rauzy, Eric Solary, Norbert Vey, Mathilde Hunault-Berger, Pierre Fenaux, Véronique Mansat-De Mas, Eric Delabesse, Philippe Guardiola, Catherine Lacombe, William Vainchenker, Claude Preudhomme, François Dreyfus, Olivier A. Bernard, Daniel Birnbaum, Michaëla Fontenay, and on behalf of the Groupe Francophone des Myélodysplasies
Blood 2009; 114: 3285-3291.
[Abstract]
[Full text]
[PDF]
The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
- Vivian G. Oehler, Ka Yee Yeung, Yongjae E. Choi, Roger E. Bumgarner, Adrian E. Raftery, and Jerald P. Radich
Blood 2009; 114: 3292-3298.
[Abstract]
[Full text]
[PDF]
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells
- Vivian G. Oehler, Katherine A. Guthrie, Carrie L. Cummings, Kathleen Sabo, Brent L. Wood, Ted Gooley, Taimei Yang, Mirjam T. Epping, Yaping Shou, Era Pogosova-Agadjanyan, Paula Ladne, Derek L. Stirewalt, Janis L. Abkowitz, and Jerald P. Radich
Blood 2009; 114: 3299-3308.
[Abstract]
[Full text]
[PDF]
AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance
- Hendrik J. M. de Jonge, Eveline S. J. M. de Bont, Peter J. M. Valk, Jan Jacob Schuringa, Marcel Kies, Carolien M. Woolthuis, Ruud Delwel, Nic J. G. M. Veeger, Edo Vellenga, Bob Löwenberg, and Gerwin Huls
Blood 2009; 114: 2869-2877.
[Abstract]
[Full text]
[PDF]
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, and Shripad S. Bhagwat
Blood 2009; 114: 2984-2992.
[Abstract]
[Full text]
[PDF]
|
|
